FDA approves Amzeeq to treat severe acne.- Foamix

Foamix Pharmaceuticals Ltd., announced that the FDA has approved its novel Amzeeq (minocycline) topical foam, 4%. Amzeeq, formerly known as FMX 101, is indicated for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris in adults and pediatric patients 9 years of age and older and is the first topical minocycline to be approved by the FDA for any condition.

Minocycline is a broad-spectrum antibiotic known for its efficacy in treating moderate to severe acne, but its use is limited in some patients due to systemic side effects when taken orally. Until now, minocycline has not been available as a topical treatment due to its instability in traditional topical formulations. In Amzeeq, Foamix has leveraged its proprietary Molecule Stabilizing Technology (MST) platform to effectively deliver minocycline in a foam-based vehicle.